SAFETY DATA SHEET

Tafluprost Formulation

Version 1.7  Revision Date: 09/13/2019  SDS Number: 558012-00008  Date of last issue: 24.04.2019  Date of first issue: 15.03.2016

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Tafluprost Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 26 Talavera Road, Talavera Corp Centre, Macquarie Park New South Wales, 2113 Australia
Telephone: (61)-02-8988-8000
Emergency telephone number: (61)-02-8988-8000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards which do not result in classification
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>56-81-5</td>
<td>&lt; 10</td>
</tr>
<tr>
<td>Tafluprost</td>
<td>209860-87-7</td>
<td>&lt; 0.3</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
None known.

Protection of first-aiders:
No special precautions are necessary for first aid responders.

Notes to physician:
Treat symptomatically and supportively.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
None known.

Specific hazards during firefighting:
Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters:
Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Soak up with inert absorbent material.
For large spills, provide dyeing or other appropriate containment to keep material from spreading. If dyed material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
SAFETY DATA SHEET
Tafluprost Formulation

Version 1.7  Revision Date: 09/13/2019  SDS Number: 558012-00008  Date of last issue: 24.04.2019
Date of first issue: 15.03.2016

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Conditions for safe storage: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Materials to avoid: Do not store with the following product types: Strong oxidizing agents.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>56-81-5</td>
<td>TWA (Mist)</td>
<td>10 mg/m³</td>
<td>AU OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tafluprost</td>
<td>209860-87-7</td>
<td>TWA</td>
<td>0.002 µg/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>0.02 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica.

Further information: Skin, Eye

Engineering measures: Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment tech-
nology designed to prevent leakage of compounds into the workplace.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type**: Organic vapour type

**Hand protection**: Chemical-resistant gloves

**Remarks**: Consider double gloving.

**Eye protection**: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection**: Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance**: Aqueous solution

**Colour**: clear

**Odour**: No data available

**Odour Threshold**: No data available

**pH**: No data available

**Melting point/freezing point**: No data available

**Initial boiling point and boiling range**: No data available

**Flash point**: No data available

**Evaporation rate**: No data available

**Flammability (solid, gas)**: Not applicable

**Flammability (liquids)**: No data available

**Upper explosion limit / Upper flammability limit**: No data available

**Lower explosion limit / Lower**: No data available
SAFETY DATA SHEET

Tafluprost Formulation

flammability limit

Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : No data available
Solubility(ies)
Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
Viscosity, kinematic : No data available
Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.
Components:
Glycerine:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity : LD50 (Guinea pig): > 5,000 mg/kg

**Tafluprost:**
Acute oral toxicity : LD50 (Rat): 665 mg/kg
LD50 (Rat): > 100 mg/kg
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : (Dog): 3 mg/kg
Application Route: Intravenous
Target Organs: Cardio-vascular system

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Glycerine:**
Species : Rabbit
Result : No skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Glycerine:**
Species : Rabbit
Result : No eye irritation

**Tafluprost:**
Species : Monkey
Result : No eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

**Tafluprost:**
Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Result : Not a skin sensitizer.
SAFETY DATA SHEET

Tafluprostan Formulation

Version: 1.7
Revision Date: 09/13/2019
SDS Number: 558012-00008
Date of last issue: 24.04.2019
Date of first issue: 15.03.2016

Chronic toxicity

Germ cell mutagenicity
Not classified based on available information.

Components:

Glycerine:
Genotoxicity in vitro
- Test Type: In vitro mammalian cell gene mutation test
  Result: negative
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: Chromosome aberration test in vitro
  Result: negative
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  Result: negative

Tafluprostan:
Genotoxicity in vitro
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: Chromosome aberration test in vitro
  Result: negative

Genotoxicity in vivo
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  Species: Mouse
  Application Route: Intraperitoneal injection
  Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Glycerine:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Tafluprostan:
Species: Rat
Application Route: Subcutaneous
Exposure time: 24 Months
Result: negative

Species: Mouse
Application Route: Subcutaneous
Exposure time: 18 Months
### Reproductive toxicity

Not classified based on available information.

#### Components:

**Glycerine:**

<table>
<thead>
<tr>
<th>Test Type: Two-generation reproduction toxicity study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
</tr>
<tr>
<td>Result: negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Ingestion</td>
</tr>
<tr>
<td>Result: negative</td>
</tr>
</tbody>
</table>

**Tafluprost:**

<table>
<thead>
<tr>
<th>Test Type: Fertility/early embryonic development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Intravenous injection</td>
</tr>
<tr>
<td>Fertility: NOAEL: 10 µg/kg</td>
</tr>
<tr>
<td>Result: No effects on fertility</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Intravenous injection</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 10 µg/kg</td>
</tr>
<tr>
<td>Result: Malformations were observed., Reduced foetal weight</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Intravenous injection</td>
</tr>
<tr>
<td>Developmental Toxicity: NOAEL: 3 µg/kg</td>
</tr>
<tr>
<td>Result: Malformations were observed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Intravenous injection</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 0.03 µg/kg</td>
</tr>
<tr>
<td>Result: Malformations were observed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Intravenous injection</td>
</tr>
<tr>
<td>Developmental Toxicity: NOAEL: 0.01 µg/kg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Intravenous injection</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 1 µg/kg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Intravenous injection</td>
</tr>
<tr>
<td>Developmental Toxicity: NOAEL:</td>
</tr>
</tbody>
</table>

**Developmental Toxicity:**

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rat</td>
</tr>
<tr>
<td>Application Route: Intravenous injection</td>
</tr>
<tr>
<td>Developmental Toxicity: LOAEL: 1 µg/kg</td>
</tr>
<tr>
<td>Result: Malformations were observed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type: Embryo-foetal development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Application Route: Intravenous injection</td>
</tr>
<tr>
<td>Developmental Toxicity: NOAEL: 0.01 µg/kg</td>
</tr>
</tbody>
</table>

**Note:**

- Results for Tests are negative.
- No effects on fertility or development observed.

---

**Result:** negative
SAFETY DATA SHEET

Tafluprost Formulation

Version 1.7
Revision Date: 09/13/2019
SDS Number: 558012-00008
Date of last issue: 24.04.2019
Date of first issue: 15.03.2016

Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 0.3 µg/kg

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.

Components:

Tafluprost:
Target Organs: Lungs, Cardio-vascular system
Assessment: Causes damage to organs.

STOT - repeated exposure
Not classified based on available information.

Components:

Tafluprost:
Target Organs: Lungs, Cardio-vascular system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Glycerine:
Species: Rat
NOAEL: 0.167 mg/l
LOAEL: 0.622 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 13 Weeks

Species: Rat
NOAEL: 8,000 - 10,000 mg/kg
Application Route: Ingestion
Exposure time: 2 yr

Species: Rabbit
NOAEL: 5,040 mg/kg
Application Route: Skin contact
Exposure time: 45 Weeks

Tafluprost:
Species: Rat
LOAEL: 0.01 mg/kg
Application Route: Intravenous
Exposure time: 6 Months
Target Organs: Cardio-vascular system, Blood, Bone marrow, Kidney, Liver, spleen
Species: Dog
NOAEL: 0.0001 mg/kg
LOAEL: 0.001 mg/kg
Application Route: Intravenous
Exposure time: 39 Weeks
Target Organs: Cardio-vascular system, Eye
Symptoms: Dilatation of the pupil

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Tafluprost:
Eye contact: Symptoms: dryness of the eyes, Blurred vision

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Glycerine:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 1,955 mg/l
Exposure time: 48 h

Toxicity to microorganisms: NOEC (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h
Method: DIN 38 412 Part 8

Persistence and degradability

Components:

Glycerine:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 92 %
Exposure time: 30 d
Method: OECD Test Guideline 301D

Bioaccumulative potential

Components:

Glycerine:
Partition coefficient: n-octanol/water: log Pow: -1.75

Tafluprost:
SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

National Regulations

ADG
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Prohibition/Licensing Requirements: There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
SECTION 16. OTHER INFORMATION

Further information
Revision Date : 09/13/2019

Date format : dd.mm.yyyy

Full text of other abbreviations
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

AU OEL / TWA : Exposure standard - time weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Civil Aviation Organization; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS mate-
Materia is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

AU / EN